Weiguo Lv
Hangzhou, Zhejiang, 310006, China
Location status: Recruiting
NCT Number: NCT03703271
Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar gestational trophoblastic neoplasia compared with the MTX single drug chemotherapy
Interested in participating?
Request Info12 year–60 year
Female
Interventional
Phase 3
Hangzhou, Zhejiang, 310006, China
Location status: Recruiting
Gestational trophoblastic neoplasia (GTN) is a group of malignant tumors derived from placental trophoblastic cells, most of which are secondary to hydatidiform mole, and 95% of GTN patients present low-risk gestational trophoblastic neoplasia(LR-GTN).In the 1960s and 1970s, with the in-depth study of the disease, it was found that the malignant tumor was highly sensitive to chemotherapy and had ideal tumor marker HCG to guide the treatment and follow-up. Therefore, GTN was the best malignant tumor with the overall cure rate of LR-GTN nearly 100%.MTX single-drug multi-course chemotherapy is the classic treatment of LR-GTN recommended by FIGO, but most patients can develop gastrointestinal, blood and liver toxicity during chemotherapy. In addition, the longer treatment cycle also brings a lot of discomfort to patients.
In recent years, some scholars proposed that the selection of treatment regimen of LR-GTN secondary to hydatidiform pregnancy should consider the toxic and side effects of chemotherapy, the maintenance of patients' physiological functions and quality of life.Retrospective studies abroad have shown that LR-GTN delayed chemotherapy for hydatidiform mole pregnancy only started chemotherapy for LR-GTN at a certain stage of progression, and the results did not change the prognosis of LR-GTN but reduced the rate of chemotherapy.In addition, for some patients with ultra-low risk of LR-GTN in hydatidiform pregnancy undergoing hysteroscopic repeat curettage , the rate of chemotherapy can be reduced, the related costs can be reduced and the quality of life of patients can be improved.
In this non-Inferiority prospective, multicenter, randomized, controlled clinical study, with the routine use of a gleam of MTX single drug treatment scheme for comparison, comparing uterine cavity again emptying delay chemotherapy guided by parallel hysteroscopy surgery clinical curative effect and adverse reaction, which discuss after hydatidiform mole ultra-low dangerous GTN patients with uterine cavity emptying again guided by hysteroscopy surgery as a line of ultra low dangerous GTN patients after hydatidiform mole security and feasibility of the treatmen
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single-agent 5-day methotrexate, two weeks a cycle
Other names: Methotrexate chemotherapy
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
Other names: complete curettage
Time frame: 2 years
The investigators may calculate the ultimate complete response rate, defined as the proportion of patients who achieve sustained normalisation of serum hCG without requiring escalation to multi-agent chemotherapy at the predefined trial endpoint.
Time frame: 2 years
The investigators may calculate the rate of response after the initial treatment of hysteroscopic repeat curettage without chemotherapy
Time frame: 2 years
The investigators may record the complications of hysteroscopic repeat curettage surgery
Time frame: 2 years
The investigators may record the adverse events of chemotherapy as assessed by the WHO
Time frame: 2 years
Overall Survival Rate of the two group patients
Time frame: 2 years
The investigators may test serum level of anti-mullerian hormone (AMH) every 6 months.
Time frame: 2 years
To calculate the pregnancy rate in an actuarial manner using the Kaplan-Meier method at the end of the trail
Time frame: 2 years
The investigators record the time of menstrual cycle resuming after chemotherapy
Women's Hospital School Of Medicine Zhejiang University
Other
A Non-Inferiority Prospective Randomized Multicenter Clinical Control Study of Hysteroscopic Repeat Curettage as the Primal Management of Low-risk Postmolar Gestational Trophoblastic Neoplasia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03785574
Female Urogenital Diseases and Pregnancy Complications, Gestational Trophoblastic Disease
Hangzhou, Zhejiang, China
View Trial DetailsNCT05139095
Female Urogenital Diseases and Pregnancy Complications, Gestational Trophoblastic Disease
Beijing, China
View Trial DetailsNCT06169644
Disease, Female Urogenital Diseases and Pregnancy Complications
Sheffield, South Yorkshire, United Kingdom
View Trial DetailsNCT06028672
Female Urogenital Diseases and Pregnancy Complications, Gestational Trophoblastic Disease
Beijing, Beijing Municipality, China
View Trial Details